Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer.
D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D008937:Mitomycins; D016685:Mitomycin; D005047:Etoposide; D011034:Podophyllotoxin